{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:48:13Z","timestamp":1791996493628,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270352"],"award-info":[{"award-number":["82270352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacl.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:44:32Z","timestamp":1756946672000},"page":"1586-1597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Joint association of plasma ceramide and renal function with coronary artery lesion severity: The CRUISE-MET study"],"prefix":"10.1016","volume":"19","author":[{"given":"Qiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.09.002_bib0002","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1097\/CM9.0000000000002741","article-title":"Changing profiles of cardiovascular disease and risk factors in China: a secondary analysis for the Global Burden of Disease Study 2019","volume":"136","author":"Wang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jacl.2025.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.09.002_bib0004","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2022.1763","article-title":"Clinical and quality-of-life outcomes following invasive versus conservative treatment of patients with chronic coronary disease across the spectrum of kidney function","volume":"7","author":"Bangalore","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0006","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.09.002_bib0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijcard.2020.08.010","article-title":"Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction","volume":"320","author":"Pan","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.diabet.2019.07.006","article-title":"Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacl.2025.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.09.002_bib0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/eurheartj\/ehz387","article-title":"Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients","volume":"41","author":"Hilvo","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.09.002_bib0012","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2337\/db23-0052","article-title":"Ceramides as risk markers for future cardiovascular events and all-cause mortality in long-standing type 1 diabetes","volume":"72","author":"Wretlind","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2025.09.002_bib0013","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-021-00488-2","article-title":"Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease","volume":"18","author":"Baek","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/clinchem\/hvac216","article-title":"High-density lipoprotein lipidomics in chronic kidney disease","volume":"69","author":"Lidgard","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2025.09.002_bib0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12933-023-01831-6","article-title":"Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study","volume":"22","author":"Liang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0016","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41586-025-08792-8","article-title":"Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis","volume":"641","author":"Zhang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2025.09.002_bib0017","unstructured":"China-Japan Friendship Hospital. Cardiovascular-renal adverse outcome risk assessment system for coronary heart disease complicated with chronic kidney disease based on targeted lipid metabolomics. https:\/\/clinicaltrials.gov\/study\/NCT06383208."},{"key":"10.1016\/j.jacl.2025.09.002_bib0018","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.09.002_bib0020","doi-asserted-by":"crossref","unstructured":"KDIGO. 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024; 105:S117-s314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"10.1016\/j.jacl.2025.09.002_bib0021","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1038\/s41467-024-52087-x","article-title":"Concordant inter-laboratory derived concentrations of ceramides in human plasma reference materials via authentic standards","volume":"15","author":"Torta","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2025.09.002_bib0022","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1210\/jc.2013-2559","article-title":"Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency","volume":"99","author":"Tarasov","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.09.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2023.342115","article-title":"Comprehensive profiling of ceramides in human serum by liquid chromatography coupled to tandem mass spectrometry combining data independent\/dependent acquisition modes","volume":"1287","author":"Luque-C\u00f3rdoba","year":"2024","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.jacl.2025.09.002_bib0024","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1007\/s00216-013-7166-9","article-title":"Development and validation of LC-MS\/MS method for determination of very long acyl chain (C22:0 and C24:0) ceramides in human plasma","volume":"405","author":"Jiang","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jacl.2025.09.002_bib0025","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00216-021-03853-z","article-title":"A simple and rapid method for extraction and measurement of circulating sphingolipids using LC-MS\/MS: a targeted lipidomic analysis","volume":"414","author":"Xu","year":"2022","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jacl.2025.09.002_bib0026","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1038\/s41598-023-31711-8","article-title":"Quartile coefficient of variation is more robust than CV for traits calculated as a ratio","volume":"13","author":"Botta-Duk\u00e1t","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacl.2025.09.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.09.016","article-title":"Adipocyte hypoxia-inducible factor 2\u03b1 suppresses atherosclerosis by promoting adipose ceramide catabolism","volume":"30","author":"Zhang","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacl.2025.09.002_bib0028","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.apsb.2021.10.001","article-title":"Disruption of adipocyte HIF-1\u03b1 improves atherosclerosis through the inhibition of ceramide generation","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jacl.2025.09.002_bib0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.matbio.2018.01.006","article-title":"Sphingolipid signaling in renal fibrosis","volume":"68-69","author":"Huwiler","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jacl.2019.03.005","article-title":"Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes","volume":"13","author":"Lopes-Virella","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0031","first-page":"768","article-title":"The relationship between kidney function and angiographically-derived SYNTAX score","volume":"27","author":"Yan","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0032","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0003319711398864","article-title":"The relationship between chronic kidney disease and SYNTAX score","volume":"62","author":"Coskun","year":"2011","journal-title":"Angiology"},{"key":"10.1016\/j.jacl.2025.09.002_bib0033","article-title":"Progression of vascular calcification and clinical outcomes in patients receiving maintenance dialysis","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2025.09.002_bib0034","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2025.09.002_bib0035","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/eurheartj\/ehac683","article-title":"Prevention of cardiorenal damage: importance of albuminuria","volume":"44","author":"Ruilope","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.09.002_bib0036","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1161\/CIRCULATIONAHA.116.024261","article-title":"Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED trial (Prevenci\u00f3n con Dieta Mediterr\u00e1nea)","volume":"135","author":"Wang","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.09.002_bib0037","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tcm.2018.05.002","article-title":"Reversal of coronary atherosclerosis: role of life style and medical management","volume":"28","author":"Parsons","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.09.002_bib0038","doi-asserted-by":"crossref","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","article-title":"Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome","volume":"99","author":"Ng","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.09.002_bib0039","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12944-023-01922-z","article-title":"Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials","volume":"22","author":"Wretlind","year":"2023","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2025.09.002_bib0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12933-025-02678-9","article-title":"Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study","volume":"24","author":"Zhao","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2025.09.002_bib0041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.09.002_bib0042","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:37:46Z","timestamp":1780472266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1933287425003861"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.09.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint association of plasma ceramide and renal function with coronary artery lesion severity: The CRUISE-MET study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}